Coles AJ - Search Results

1

Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H.

Paolillo A, Coles AJ, Molyneux PD, Gawne-Cain M, MacManus D, Barker GJ, Compston DA, Miller DH. Paolillo A, et al. Among authors: coles aj. Neurology. 1999 Sep 11;53(4):751-7. doi: 10.1212/wnl.53.4.751. Neurology. 1999. PMID: 10489036

2

Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features.

Tubridy N, Coles AJ, Molyneux P, Compston DA, Barkhof F, Thompson AJ, McDonald WI, Miller DH. Tubridy N, et al. Among authors: coles aj. Brain. 1998 Feb;121 ( Pt 2):225-31. doi: 10.1093/brain/121.2.225. Brain. 1998. PMID: 9549501 Clinical Trial.

3

Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis.

Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, Hale G, Miller D, Waldmann H, Compston A. Coles AJ, et al. Ann Neurol. 1999 Sep;46(3):296-304. doi: 10.1002/1531-8249(199909)46:3<296::aid-ana4>3.0.co;2-#. Ann Neurol. 1999. PMID: 10482259 Clinical Trial.

4

Disease activity and the immune set in multiple sclerosis: blood markers for immunotherapy.

Coles AJ, Wing MG, Compston DA. Coles AJ, et al. Mult Scler. 1998 Jun;4(3):232-8. doi: 10.1177/135245859800400327. Mult Scler. 1998. PMID: 9762680

5

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.

Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA. Coles AJ, et al. Neurology. 2012 Apr 3;78(14):1069-78. doi: 10.1212/WNL.0b013e31824e8ee7. Epub 2012 Mar 21. Neurology. 2012. PMID: 22442431 Clinical Trial.

6

Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy.

Marsh EA, Hirst CL, Llewelyn JG, Cossburn MD, Reilly MM, Krishnan A, Doran M, Ryan AM, Coles AJ, Jones JL, Robertson NP. Marsh EA, et al. Among authors: coles aj. J Neurol. 2010 Jun;257(6):913-9. doi: 10.1007/s00415-009-5437-3. Epub 2010 Jan 6. J Neurol. 2010. PMID: 20049473 Clinical Trial.

7

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

CAMMS223 Trial Investigators; Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK. CAMMS223 Trial Investigators, et al. Among authors: coles aj. N Engl J Med. 2008 Oct 23;359(17):1786-801. doi: 10.1056/NEJMoa0802670. N Engl J Med. 2008. PMID: 18946064 Free article. Clinical Trial.

8

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis.

Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C, Weetman A, Hale G, Chatterjee VK, Waldmann H, Compston A. Coles AJ, et al. Lancet. 1999 Nov 13;354(9191):1691-5. doi: 10.1016/S0140-6736(99)02429-0. Lancet. 1999. PMID: 10568572 Clinical Trial.

9

Rapidly reversible dementia in cerebral amyloid inflammatory vasculopathy.

Harkness KA, Coles A, Pohl U, Xuereb JH, Baron JC, Lennox GG. Harkness KA, et al. Eur J Neurol. 2004 Jan;11(1):59-62. doi: 10.1046/j.1351-5101.2003.00707.x. Eur J Neurol. 2004. PMID: 14692890

10

Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis.

Costelloe L, Jones J, Coles A. Costelloe L, et al. Expert Rev Neurother. 2012 Mar;12(3):335-41. doi: 10.1586/ern.12.5. Expert Rev Neurother. 2012. PMID: 22364332 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

91 results

Search Page

Filters